Prophylactic protein free synthetic surfactant for preventing morbidity and mortality in preterm infants
about
Overview of ventilation strategies for the early management of intubated preterm infantsSurfactant for meconium aspiration syndrome in term and late preterm infantsDelayed introduction of progressive enteral feeds to prevent necrotising enterocolitis in very low birth weight infantsAnimal derived surfactant extract versus protein free synthetic surfactant for the prevention and treatment of respiratory distress syndromeAnimal derived surfactant extract versus protein free synthetic surfactant for the prevention and treatment of respiratory distress syndromeNebulised surfactant in preterm infants with or at risk of respiratory distress syndromeProphylactic versus selective use of surfactant in preventing morbidity and mortality in preterm infantsSurfactant for pulmonary haemorrhage in neonatesDelayed introduction of progressive enteral feeds to prevent necrotising enterocolitis in very low birth weight infantsEarly versus delayed selective surfactant treatment for neonatal respiratory distress syndromeDelayed introduction of progressive enteral feeds to prevent necrotising enterocolitis in very low birth weight infantsThe use of surfactant in the neonatal period- the known aspects, those still under research and those which need to be investigated furtherThe Role of Surfactant in Lung Disease and Host Defense against Pulmonary InfectionsA systematic review of randomized controlled trials for the prevention of bronchopulmonary dysplasia in infants.Can evidence-based medicine and clinical quality improvement learn from each other?Exogenous surfactant therapy in 2013: what is next? Who, when and how should we treat newborn infants in the future?Poractant alfa versus bovine lipid extract surfactant for infants 24+0 to 31+6 weeks gestational age: A randomized controlled trial.The role of patent ductus arteriosus and its treatments in the development of bronchopulmonary dysplasiaNeonatal posthemorrhagic hydrocephalus from prematurity: pathophysiology and current treatment conceptsAnalysis of nitric oxide synthase gene polymorphisms in neonatal respiratory distress syndrome among the Chinese Han population.The Efficacy of Surfactant Replacement Therapy in the Growth-Restricted Preterm Infant: What is the Evidence?Association between Interleukin-10-1082 G/A and Tumor Necrosis Factor-α 308 G/A Gene Polymorphisms and Respiratory Distress Syndrome in Iranian Preterm Infants.Remifentanil for endotracheal intubation in premature infants: A randomized controlled trialIs it feasible to identify preterm infants with respiratory distress syndrome for early extubation to continuous positive airway pressure post-surfactant treatment during retrieval?Opportunities in posthemorrhagic hydrocephalus research: outcomes of the Hydrocephalus Association Posthemorrhagic Hydrocephalus Workshop.Protein-free synthetic surfactant for the prevention and treatment of respiratory distress syndrome in neonates
P2860
Q24186988-92550C1C-E091-4754-B115-F253443D49E0Q24187318-955057F3-88B8-440F-97BB-505D7C8B6D5EQ24187497-99FBEAC3-E9B9-4DFE-AD47-006E2FED8BD8Q24187777-C2E0AF71-88CA-4D29-9EAE-831B5DE5E944Q24187839-AD44C656-6474-4DF5-8D48-DCBD4797450BQ24198153-2EEED64E-A3D9-4837-AB52-D36BD764A064Q24201075-A70D46E5-C606-4B16-8F0D-D230E4131A7FQ24201963-D7D312ED-5AA0-4DB7-9E53-1467EAEBF143Q24202657-0A77A254-16DF-4CFA-A81B-3CC6CD4C2545Q24202890-401763F8-53B7-4331-8EE0-84D044C2C8B7Q24235703-9790BC80-F726-42FF-89DD-1D7D27CE6A57Q26864160-1CCD0A0D-41E6-4769-954F-5EA244AEF1C1Q26865690-26475661-C9F6-40DA-9976-52799644C517Q34123512-72A521D0-CB9F-4D40-924B-B02879C7FB66Q34735861-7CC5C307-A42D-4F85-848A-13D907A51C32Q35013615-F036D83C-9A9D-4A0C-8BF7-8873893ADBEDQ36362972-858D9562-C13B-4639-B64B-12208F4A48B1Q36768333-51BC9339-4C19-4611-B3CA-3E2032DBF41FQ37347049-E29A863E-2BC1-42F7-8475-1B77EB6AF629Q37717240-CD021660-4A9E-4C2B-BB88-48CF1ED845B8Q38268677-AC29B796-DA44-43CE-8F7F-A489316F8999Q40290348-503A9180-1026-4934-A9B7-6DDA7C23088FQ41561967-B8794786-114B-4A09-A316-2BC51D297991Q51699154-1AF532DD-2EB7-4B2D-957A-B037AF782C12Q55069307-C4E33E2C-DA88-4249-93A2-AEDD2B3CA7C1Q57570428-4C683E7C-1818-4AC5-B1DC-A2A103783EE0
P2860
Prophylactic protein free synthetic surfactant for preventing morbidity and mortality in preterm infants
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
name
Prophylactic protein free synt ...... d mortality in preterm infants
@ast
Prophylactic protein free synt ...... d mortality in preterm infants
@en
Prophylactic protein free synt ...... d mortality in preterm infants
@en-gb
Prophylactic protein free synt ...... d mortality in preterm infants
@nl
type
label
Prophylactic protein free synt ...... d mortality in preterm infants
@ast
Prophylactic protein free synt ...... d mortality in preterm infants
@en
Prophylactic protein free synt ...... d mortality in preterm infants
@en-gb
Prophylactic protein free synt ...... d mortality in preterm infants
@nl
prefLabel
Prophylactic protein free synt ...... d mortality in preterm infants
@ast
Prophylactic protein free synt ...... d mortality in preterm infants
@en
Prophylactic protein free synt ...... d mortality in preterm infants
@en-gb
Prophylactic protein free synt ...... d mortality in preterm infants
@nl
P1476
Prophylactic protein free synt ...... d mortality in preterm infants
@en
P2093
P356
10.1002/14651858.CD001079.PUB2
P50
P577
2010-01-20T00:00:00Z